Extended Data Fig. 3: Decrease in Soluble LAG-3 Levels Driven by Relatlimab Trough Concentration (Ctrough) Exposure. | Nature Medicine

Extended Data Fig. 3: Decrease in Soluble LAG-3 Levels Driven by Relatlimab Trough Concentration (Ctrough) Exposure.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Extended Data Fig. 3

Center lines represent medians, the bounds of the boxes indicate the 25th and 75th percentiles, the whiskers represent the minima and maxima, and dots represent outliers; baseline = last non-missing result with a collection date-time less than or equal to the date-time of the first active dose of study medication; Q1 = [0.0892-8.7000); Q2 = [8.7000-13.2790); Q3 = [13.2790-19.5397); Q4 = [19.5397-50.5000].

Back to article page